intratumoral STING receptor agonist
in Ph. I for adv. solid tumors as single agent
from macrocyclization of cyclic dinucleotide
ChemMedChem., Jan. 31, 2021
Eisai Inc., Cambridge, MA
3. The Eisai STING agonist E7766 leads to tumor eradication in 9/10 treated animals in a syngeneic model when injected intratumorally, and is currently in a Ph. I study for advanced solid tumors. The molecule has an interesting macrocyclic structure, and behaves as a cyclic dinucleotide mimic with potent activity on all four human STING variants.